Dysregulation of PFKFB2 has been linked to several metabolic disorders, including diabetes [37], obesity [37], and cancer [38], making it a promising therapeutic target for these diseases. Here, PFKFB2 is linked to obesity due to melanocortin 4 receptor deficiency.